<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154774">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01085045</url>
  </required_header>
  <id_info>
    <org_study_id>PT0031002</org_study_id>
    <nct_id>NCT01085045</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (7 Days), Four-Period, Eight-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Two Doses of PT003, Two Doses of PT005 and One Dose of PT001 in Patients With Moderate to Very Severe COPD, Compared With Foradil® Aerolizer® (12 μg, Open-Label) and Spiriva® Handihaler® (18 μg, Open-Label) as Active Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate, after 1 week of dosing, the efficacy and safety of
      PT003 compared with its individual components (PT001 and PT005), placebo and two active
      comparators to demonstrate superiority of the combination to its components, and to assess
      the relative contribution of the components compared with placebo, in patients with moderate
      to very severe COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in forced expiratory volume in one second (FEV1) area under the curve from 0 to 12 hours [AUC(0-12)] from test day baseline</measure>
    <time_frame>Day 7</time_frame>
    <description>Day 7 time points for FEV1 are measured over 12 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1, time to onset of action (greater than or equal to 10% improvement in mean FEV1), proportion of patients with greater than or equal to 12% improvement in FEV1 and peak improvement in inspiratory capacity (IC)</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 timepoints for FEV1 and IC are measured over 2 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in pre-dose FEV1, peak FEV1, peak improvement in IC, and trough FEV1</measure>
    <time_frame>Day 7</time_frame>
    <description>Day 7 time points for FEV1 are measured over 12 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean daily peak expiratory flow rate</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Inhaled PT003 (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT003 MDI Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled PT003 (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT003 MDI Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled PT005 (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT005 MDI Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled PT005 (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT005 MDI Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium bromide 18 μg (Spiriva Handihaler®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium Bromide inhalation powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol Fumarate 12 μg (Foradil® Aerolizer®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol fumarate inhalation powder 12 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled PT001 (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT001 MDI Dose 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT003 MDI</intervention_name>
    <description>Inhaled PT003 MDI administered as two puffs BID for 7 days</description>
    <arm_group_label>Inhaled PT003 (Dose 1)</arm_group_label>
    <arm_group_label>Inhaled PT003 (Dose 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT005 MDI</intervention_name>
    <description>Inhaled PT005 MDI administered as two puffs BID for 7 days</description>
    <arm_group_label>Inhaled PT005 (Dose 1)</arm_group_label>
    <arm_group_label>Inhaled PT005 (Dose 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo MDI</intervention_name>
    <description>Inhaled placebo administered as two puffs BID for 7 days</description>
    <arm_group_label>Inhaled Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium bromide 18 μg (Spiriva Handihaler®)</intervention_name>
    <description>Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days</description>
    <arm_group_label>Tiotropium bromide 18 μg (Spiriva Handihaler®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Fumarate 12 μg (Foradil® Aerolizer®)</intervention_name>
    <description>Inhaled formoterol fumarate 12 μg (Foradil® Aerolizer®) administered BID for 7 days</description>
    <arm_group_label>Formoterol Fumarate 12 μg (Foradil® Aerolizer®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT001 MDI</intervention_name>
    <description>Inhaled PT001 MDI administered as two puffs BID for 7 days</description>
    <arm_group_label>Inhaled PT001 (Dose 1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  40 - 80 years of age

          -  Clinical history of COPD with airflow limitation that is not fully reversible

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test; and acceptable contraceptive methods

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  A measured post- bronchodilator FEV1/FVC ratio of &lt; or = 0.70

          -  A measured post- bronchodilator FEV1 &gt; or = 750ml or 30% predicted and &lt; or = 80% of
             predicted normal values

          -  Able to change COPD treatment as required by protocol

        Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Primary diagnosis of asthma

          -  Alpha-1 antitrypsin deficiency as the cause of COPD

          -  Active pulmonary diseases

          -  Prior lung volume reduction surgery

          -  Abnormal chest X-ray (or CT scan) not due to the presence of COPD

          -  Hospitalized due to poorly controlled COPD within 3 months of Screening

          -  Clinically significant medical conditions that preclude participation in the study
             (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma,
             symptomatic prostatic hypertrophy)

          -  Cancer that has not been in complete remission for at least 5 years

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives

        Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Southern Oregon, PC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austrials</name>
      <address>
        <city>Caringbah</city>
        <state>New South Wales</state>
        <zip>2229</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woolcock</name>
      <address>
        <city>Glebe</city>
        <state>New South Wales</state>
        <zip>2037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austrials</name>
      <address>
        <city>Hornsby</city>
        <state>New South Wales</state>
        <zip>2077</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austrials</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Q-Pharm</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Research Foundation - Burnside War Memorial Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lung Institute of WA</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenlane Clinical Centre</name>
      <address>
        <city>Epsom</city>
        <state>Auckland</state>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZ Respiratory &amp; Sleep Institute</name>
      <address>
        <city>Greenlane East</city>
        <state>Auckland</state>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Waikato</state>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P3 Research</name>
      <address>
        <city>Crofton Downs</city>
        <state>Wellington</state>
        <zip>6143</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 11, 2012</lastchanged_date>
  <firstreceived_date>March 9, 2010</firstreceived_date>
  <firstreceived_results_disposition_date>September 11, 2012</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
